Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center.
the Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston.
Laryngoscope. 2020 Jan;130(1):86-93. doi: 10.1002/lary.27849. Epub 2019 Feb 1.
To evaluate long-term global and site-specific health-related quality of life (HRQoL) in patients treated for sinonasal and nasopharyngeal malignancies.
Cross-sectional.
One hundred fourteen patients with sinonasal and nasopharyngeal malignancies received surgery, radiation, systemic chemotherapy, or a combination thereof, with curative intent. Validated global ([EuroQol-5D] Visual Analogue Scale [EQ-5D VAS]) and disease-specific instruments (MD Anderson Symptom Inventory-Head and Neck [MDASI-HN], Anterior Skull Base Questionnaire [ASBQ]) were administered to patients who were both free of disease and had completed treatment at least 12 months previously. Associations between instruments, instrument domains, and specific clinical parameters were analyzed.
The median age was 55 years. The mean EQ-5D VAS, MDASI-22 composite score, and ASBQ score were 74 (standard deviation [SD] 21), 48 (SD 36), and 130 (SD 27), respectively. The most frequently reported high-severity items in MDASI-HN were dry mouth and difficulty tasting food. The most frequently reported high-severity items in ASBQ were difficulty with smell and nasal secretions. Advanced Tumor (T) classification was associated with worse overall ASBQ sum score (P = 0.02). ASBQ performance at home and MDASI-HN drowsy symptom items independently predicted worse global HRQoL as measured by the EQ-5D VAS (P < 0.001).
Global HRQoL for survivors of sinonasal and nasopharyngeal malignancies after multimodality treatment approximates that of the U.S. population for the same age group. ASBQ and MDASI-HN correlate well with global HRQoL outcomes as measured by EQ-5D VAS. MDASI-HN and ASBQ elicited unique symptoms, highlighting the complex symptom burden experienced by these patients. Further studies should identify patients predisposed to reduced long-term QOL.
3 Laryngoscope, 130:86-93, 2020.
评估接受鼻窦和鼻咽恶性肿瘤治疗的患者的长期整体和特定部位健康相关生活质量（HRQoL）。
横断面研究。
114 例鼻窦和鼻咽恶性肿瘤患者接受了根治性手术、放疗、全身化疗或联合治疗。对无疾病且治疗结束至少 12 个月的患者进行了有效的全球量表（欧洲五维健康量表-视觉模拟量表 [EQ-5D VAS]）和疾病特异性量表（安德森症状指数-头颈部 [MDASI-HN]，前颅底问卷 [ASBQ]）评估。分析了各量表之间、各量表各维度之间以及特定临床参数之间的相关性。
中位年龄为 55 岁。平均 EQ-5D VAS、MDASI-22 综合评分和 ASBQ 评分为 74（标准差 [SD] 21）、48（SD 36）和 130（SD 27）。MDASI-HN 中报告频率最高的高严重度项目为口干和味觉障碍。ASBQ 中报告频率最高的高严重度项目为嗅觉和鼻腔分泌物问题。高级肿瘤（T）分类与整体 ASBQ 总分较差相关（P = 0.02）。ASBQ 在家中的表现和 MDASI-HN 困倦症状项目独立预测 EQ-5D VAS 测量的整体 HRQoL 更差（P < 0.001）。
经过多模式治疗后，鼻窦和鼻咽恶性肿瘤幸存者的全球 HRQoL 接近同年龄组美国人群的 HRQoL。ASBQ 和 MDASI-HN 与 EQ-5D VAS 测量的全球 HRQoL 结果相关性良好。MDASI-HN 和 ASBQ 引出了独特的症状，突出了这些患者所经历的复杂症状负担。进一步的研究应确定哪些患者有降低长期 QOL 的倾向。
3 级。喉镜，130：86-93，2020 年。
